A detailed history of Seascape Capital Management transactions in Eli Lilly & CO stock. As of the latest transaction made, Seascape Capital Management holds 1,614 shares of LLY stock, worth $1.23 Million. This represents 0.51% of its overall portfolio holdings.

Number of Shares
1,614
Previous 1,611 0.19%
Holding current value
$1.23 Million
Previous $1.46 Million 1.99%
% of portfolio
0.51%
Previous 0.54%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$772.14 - $960.02 $2,316 - $2,880
3 Added 0.19%
1,614 $1.43 Million
Q2 2024

Jul 30, 2024

BUY
$724.87 - $909.04 $2,174 - $2,727
3 Added 0.19%
1,611 $1.46 Million
Q1 2024

Apr 29, 2024

SELL
$592.2 - $792.28 $69,879 - $93,489
-118 Reduced 6.84%
1,608 $1.25 Million
Q4 2023

Jan 29, 2024

SELL
$525.19 - $619.13 $1,575 - $1,857
-3 Reduced 0.17%
1,726 $1.01 Million
Q3 2023

Nov 09, 2023

BUY
$434.7 - $599.3 $9,998 - $13,783
23 Added 1.35%
1,729 $928,000
Q2 2023

Aug 04, 2023

BUY
$350.74 - $468.98 $113,990 - $152,418
325 Added 23.53%
1,706 $800,000
Q1 2023

May 01, 2023

BUY
$310.63 - $364.82 $31,063 - $36,482
100 Added 7.81%
1,381 $474,000
Q4 2022

Jan 31, 2023

SELL
$321.55 - $374.67 $21,222 - $24,728
-66 Reduced 4.9%
1,281 $469,000
Q3 2022

Nov 08, 2022

BUY
$296.48 - $337.87 $155,652 - $177,381
525 Added 63.87%
1,347 $436,000
Q2 2022

Aug 09, 2022

BUY
$278.73 - $327.27 $1,672 - $1,963
6 Added 0.74%
822 $267,000
Q1 2022

May 09, 2022

BUY
$234.69 - $291.66 $2,346 - $2,916
10 Added 1.24%
816 $234,000
Q4 2021

Jan 27, 2022

BUY
$224.85 - $279.04 $181,229 - $224,906
806 New
806 $223,000
Q1 2020

May 28, 2020

SELL
$119.05 - $147.35 $188,218 - $232,960
-1,581 Closed
0 $0
Q4 2019

Feb 13, 2020

BUY
$106.92 - $132.43 $169,040 - $209,371
1,581 New
1,581 $208,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $727B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Seascape Capital Management Portfolio

Follow Seascape Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Seascape Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Seascape Capital Management with notifications on news.